NCT06892288
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
Registry fields
- Overall status
- ACTIVE_NOT_RECRUITING
- Conditions
- Phosphomannomutase 2 Deficiency, PMM2-CDG
- Study type
- INTERVENTIONAL
- Phase
- PHASE2, PHASE3
- Primary purpose
- TREATMENT
- Intervention type
- DRUG
- Interventions
- GLM101 (Part A, Double-blind), Placebo (Part A, Double-blind), GLM101 (Part B, Open-label)
- Lead sponsor
- Glycomine, Inc. (INDUSTRY)
Cached at: 2026-08-15 00:58:58
Brief summary
This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researchers will compare participants receiving GLM101 to those receiving a placebo to see if GLM101 improves symptoms of PMM2-CDG.
The study includes two treatment parts: a 24-week double blind placebo-controlled treatment period (Part A), and a 24-week open-label phase where every participant will receive GLM101(Part B).
The study includes two treatment parts: a 24-week double blind placebo-controlled treatment period (Part A), and a 24-week open-label phase where every participant will receive GLM101(Part B).
Contact
Need a report or Korean medical writing based on this trial?
Sign in with Kakao to continue